{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:36:03Z","timestamp":1789014963183,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00277-019-03621-1","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T01:14:04Z","timestamp":1548378844000},"page":"713-722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4072-7592","authenticated-orcid":false,"given":"Annamaria","family":"Brioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Klaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Sayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inken","family":"Hilgendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Scherag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaposi","family":"Yomade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars-Olof","family":"M\u00fcgge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"von Lilienfeld-Toal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"key":"3621_CR1","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516\u20132520. \n                    https:\/\/doi.org\/10.1182\/blood-2007-10-116129","journal-title":"Blood"},{"key":"3621_CR2","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122\u20131128. \n                    https:\/\/doi.org\/10.1038\/leu.2013.313","journal-title":"Leukemia"},{"key":"3621_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2005-02-0522","volume":"106","author":"M Cavo","year":"2005","unstructured":"Cavo M, Zamagni E, Tosi P et al (2005) Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106:35\u201339. \n                    https:\/\/doi.org\/10.1182\/blood-2005-02-0522","journal-title":"Blood"},{"key":"3621_CR4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3324\/haematol.2011.043372","volume":"97","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Johnson PRE, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA, for the National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group (2012) Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC myeloma IX randomized trial results. Haematologica 97:442\u2013450. \n                    https:\/\/doi.org\/10.3324\/haematol.2011.043372","journal-title":"Haematologica"},{"key":"3621_CR5","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"M Cavo","year":"2010","unstructured":"Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M, GIMEMA Italian Myeloma Network (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376:2075\u20132085. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(10)61424-9","journal-title":"Lancet"},{"key":"3621_CR6","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IGH, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GMJ, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J Clin Oncol Off J Am Soc Clin Oncol 30:2946\u20132955. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.39.6820","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3621_CR7","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, Multiple Myeloma (009) Study Investigators (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133\u20132142. \n                    https:\/\/doi.org\/10.1056\/NEJMoa070596","journal-title":"N Engl J Med"},{"key":"3621_CR8","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Fo\u00e0 R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD, Multiple Myeloma (010) Study Investigators (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123\u20132132. \n                    https:\/\/doi.org\/10.1056\/NEJMoa070594","journal-title":"N Engl J Med"},{"key":"3621_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR, Eastern Cooperative Oncology Group (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11:29\u201337. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(09)70284-0","journal-title":"Lancet Oncol"},{"key":"3621_CR10","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"J San Miguel","year":"2013","unstructured":"San Miguel J, Weisel K, Moreau P et al (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14:1055\u20131066. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(13)70380-2","journal-title":"Lancet Oncol"},{"key":"3621_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosi\u00f1ol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ, ENDEAVOR Investigators (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17:27\u201338. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)00464-7","journal-title":"Lancet Oncol"},{"key":"3621_CR12","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, di Bacco A, Hui AM, van de Velde H, Richardson PG, TOURMALINE-MM1 Study Group (2016) Oral Ixazomib, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374:1621\u20131634. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1516282","journal-title":"N Engl J Med"},{"key":"3621_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/17474086.2017.1284584","volume":"10","author":"A Brioli","year":"2017","unstructured":"Brioli A, M\u00fcgge L-O, Hochhaus A, Von Lilienfeld-Toal M (2017) Safety issues and management of toxicities associated with new treatments for multiple myeloma. Expert Rev Hematol 10:193\u2013205. \n                    https:\/\/doi.org\/10.1080\/17474086.2017.1284584","journal-title":"Expert Rev Hematol"},{"key":"3621_CR14","doi-asserted-by":"publisher","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2005","unstructured":"Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, Behrens J, Smith A, Child JA, Drayson MT (2005) Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council adult Leukaemia working party. J Clin Oncol Off J Am Soc Clin Oncol 23:9219\u20139226. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.03.2086","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3621_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist U-H, Landgren O, Bjorkholm M, Hultcrantz M, Kjellander C, Turesson I, Kristinsson SY (2015) Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 100:107\u2013113. \n                    https:\/\/doi.org\/10.3324\/haematol.2014.107714","journal-title":"Haematologica"},{"key":"3621_CR16","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","volume":"26","author":"A Chanan-Khan","year":"2008","unstructured":"Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Neuwirth R, Anderson KC, Richardson PG (2008) Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol Off J Am Soc Clin Oncol 26:4784\u20134790. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.14.9641","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3621_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bjh.13532","volume":"171","author":"BW Teh","year":"2015","unstructured":"Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA (2015) Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol 171:100\u2013108. \n                    https:\/\/doi.org\/10.1111\/bjh.13532","journal-title":"Br J Haematol"},{"key":"3621_CR18","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau J-L, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J, on behalf of the International Myeloma Workshop Consensus Panel 1 (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the international myeloma workshop consensus panel 1. Blood 117:4691\u20134695. \n                    https:\/\/doi.org\/10.1182\/blood-2010-10-299487","journal-title":"Blood"},{"key":"3621_CR19","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","volume":"49","author":"M Nucci","year":"2009","unstructured":"Nucci M, Anaissie E (2009) Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis Off Publ Infect Dis Soc Am 49:1211\u20131225. \n                    https:\/\/doi.org\/10.1086\/605664","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"3621_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00277-013-1951-6","volume":"93","author":"C K\u00f6nig","year":"2014","unstructured":"K\u00f6nig C, Kleber M, Reinhardt H, Knop S, W\u00e4sch R, Engelhardt M (2014) Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients. Ann Hematol 93:479\u2013484. \n                    https:\/\/doi.org\/10.1007\/s00277-013-1951-6","journal-title":"Ann Hematol"},{"key":"3621_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/ejh.13066","volume":"101","author":"R S\u00f8rrig","year":"2018","unstructured":"S\u00f8rrig R, Klausen TW, Salomo M, Vangsted A, Gimsing P (2018) Risk factors for blood stream infections in multiple myeloma: a population-based study of 1154 patients in Denmark. Eur J Haematol 101:21\u201327. \n                    https:\/\/doi.org\/10.1111\/ejh.13066","journal-title":"Eur J Haematol"},{"key":"3621_CR22","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00277-015-2447-3","volume":"94","author":"M Sandherr","year":"2015","unstructured":"Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O, Biehl L, Cornely OA (2015) Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the guidelines of the infectious diseases working party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol 94:1441\u20131450. \n                    https:\/\/doi.org\/10.1007\/s00277-015-2447-3","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03621-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03621-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03621-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T19:09:17Z","timestamp":1579806557000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03621-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["3621"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03621-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,24]]},"assertion":[{"value":"26 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The present study was conducted after approval by the institutional review board at Jena University Hospital in Germany. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. As data analyzed were pseudonimized data normally collected during clinical practice, the responsible ethic committee was of the opinion\u00a0that no extra informed consent was needed for the present research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}},{"value":"AB: Honoraria: Celgene, Takeda, Travel support: Janssen, Celgene, Takeda, Research support: Celgene; IH: Research support: Medac, Novartis, Travel support: Medac, Novartis, Gilead; LOM: Research support: Celgene, Honoraria: Celgene, Janssen, Novartis, Amgen, Bristol Myers Squibb; MvLT: Honoraria: Janssen, Celgene, Novartis, Takeda, Travel support: Janssen, Celgene, Novartis, Takeda, Research support: Janssen, Celgene, Novartis, Takeda; the other authors have no relevant conflict of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}